Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Update

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 644,912 shares, a growth of 57.8% from the January 15th total of 408,588 shares. Currently, 2.0% of the company’s shares are sold short. Based on an average daily volume of 246,539 shares, the days-to-cover ratio is currently 2.6 days. Based on an average daily volume of 246,539 shares, the days-to-cover ratio is currently 2.6 days. Currently, 2.0% of the company’s shares are sold short.

Institutional Trading of Oramed Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. BML Capital Management LLC grew its stake in Oramed Pharmaceuticals by 2.7% during the 3rd quarter. BML Capital Management LLC now owns 3,167,231 shares of the biotechnology company’s stock worth $8,361,000 after buying an additional 83,978 shares during the last quarter. Marshall Wace LLP acquired a new stake in Oramed Pharmaceuticals in the fourth quarter worth about $738,000. Bank of America Corp DE grew its stake in shares of Oramed Pharmaceuticals by 4.4% during the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after acquiring an additional 6,261 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Oramed Pharmaceuticals by 31.2% during the fourth quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 18,600 shares in the last quarter. Finally, HRT Financial LP purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter valued at approximately $131,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Price Performance

Oramed Pharmaceuticals stock traded up $0.08 during trading hours on Friday, reaching $3.25. The stock had a trading volume of 62,934 shares, compared to its average volume of 193,888. The company has a market cap of $129.36 million, a price-to-earnings ratio of 2.58 and a beta of 1.34. The business’s 50 day moving average price is $3.22 and its 200-day moving average price is $2.65. Oramed Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $3.71.

Oramed Pharmaceuticals Announces Dividend

The company also recently declared a dividend, which was paid on Monday, January 26th. Shareholders of record on Friday, January 16th were issued a $0.25 dividend. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals’s payout ratio is currently 19.84%.

Analysts Set New Price Targets

Several equities analysts have recently commented on ORMP shares. Weiss Ratings restated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised shares of Oramed Pharmaceuticals to a “hold” rating in a research note on Saturday, November 1st. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Oramed Pharmaceuticals currently has a consensus rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.